中文名稱  MED17抗體費用 

英文名稱  Anti-TRAP80/MED17/CRSP77

別    名 Activator recruited cofactor 77 kDa component; Activator-recruited cofactor 77 kDa component; ARC77; Cofactor required for Sp1 transcriptional activation subunit 6; CRSP complex subunit 6; CRSP6; CRSP77; DRIP80; med17; MED17_HUMAN; Mediator complex subunit 17; Mediator of RNA polymerase II transcription subunit 17; Thyroid hormone receptor-associated protein complex 80 kDa component; Transcriptional coactivator CRSP77; Trap80; Vitamin D3 receptor-interacting protein complex 80 kDa component.

產(chǎn)品屬性：

MED17抗體費用 濃    度  1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep

產(chǎn)品類型   一抗  

研究領(lǐng)域    神經(jīng)生物學 信號轉(zhuǎn)導 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學

蛋白分子量  predicted molecular weight: 73kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated synthetic peptide derived from human TRAP80/MED17/CRSP77 (181-280aa)

亞    型  IgG

純化方法   affinity purified by Protein A

儲 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

MED17抗體費用 產(chǎn)品應(yīng)用   WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 In mammalian cells, transcription is regulated in part by high molecular weight coactivating complexes that mediate signals between transcriptional activators and RNA polymerase (1). These complexes include CRSP (for cofactor required for Sp1 activation), which is required, in conjunction with TAFIIs, for transcriptional activation by Sp1 (2). CRSP is ubiquitously expressed in various tissues and functions as a multimeric complex that consists of nine distinct subunits (3). Several members of the CRSP family share sequence similarity with multiple components of the yeast transcriptional mediator proteins, including CRSP150, which is related to yeast Rgr1, and CRSP70, which is similar to the elongation factor TFIIS (4). CRSP77 and CRSP150 are also related to proteins within the putative murine mediator complex, while CRSP130 and CRSP34 are largely unrelated to either murine or yeast proteins (2,5). CRSP subunits also associate with larger multimeric coactivaor complexes, including ARC/DRI, which binds directly to SREBP and nuclear hormone receptors to facilitate transcription, and with NAT, a polymerase II-interacting complex that represses activated transcription (6,7).

Function : Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors.

Subunit : Interacts with GATA1 and PPARG (By similarity). Component of the Mediator complex, which is composed of MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct module termed the CDK8 module. Mediator containing the CDK8 module is less active than Mediator lacking this module in supporting transcriptional activation. Individual preparations of the Mediator complex lacking one or more distinct subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and TRAP. Interacts with STAT2.

Subcellular Location : Nucleus.

Tissue Specificity : Ubiquitous.

Post-translational modifications : Phosphorylated upon DNA damage, probably by ATM or ATR.

DISEASE : Defects in MED17 are the cause of microcephaly postnatal progressive with seizures and brain atrophy (MCPHSBA) [MIM:613668]. It is a disorder characterized by postnatal progressive microcephaly and severe developmental retardation associated with cerebral and cerebellar atrophy. Infants manifest swallowing difficulties leading to failure to thrive, jitteriness, poor visual fixation, truncal arching, seizures. There is no acquisition of developmental milestones and patients suffer from marked spasticity and profound retardation. Progressive microcephaly becomes evident few months after birth.

Similarity : Belongs to the Mediator complex subunit 17 family.

Database links : UniProtKB/Swiss-Prot: Q9NVC6.2

實驗流程：

全、新、優(yōu)、品、好四大特點：

MED17抗體費用 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標準品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團隊，產(chǎn)品一旦售出，實驗過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時沒有任何的后顧之憂。

技術(shù)外包服務(wù):

★MED17抗體費用 分子生物學：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學：基因合成、引物合成、基因測序、載體構(gòu)建等

★蛋白工程：原核、哺乳動物蛋白表達系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細胞工程：細胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復、克隆形成)、細胞培養(yǎng)、細胞膜制備、穩(wěn)定細胞株構(gòu)建、細胞RNAi技術(shù)等等。

正在熱銷的相關(guān)產(chǎn)品：

Anti-TNFSF18/GITR Ligand/FITC 熒光素標記壞死因子配體超家族成員18抗體IgGMulti-class antibodies規(guī)格： 0.2ml

BMP4(bone morphogenetic protein 4) 骨形態(tài)發(fā)生蛋白4(抗原)Multi-class antibodies規(guī)格： 0.5mg

調(diào)節(jié)蛋白抗體 Anti-TM 0.2ml

5HT2A Receptor 英文名稱： 5-羥色胺受體2A抗體 0.2ml

ETFA 英文名稱： 電子轉(zhuǎn)移黃素蛋白α抗體 0.2ml

Rhesus antibody Rh phospho-JunB(Ser79) 磷酸化活化蛋白激酶B抗體 規(guī)格 0.1ml

BMP4(bone morphogenetic protein 4) 骨形態(tài)發(fā)生蛋白4(抗原)Multi-class antibodies規(guī)格： 0.5mg

Anti-p-PKC beta 1/2/FITC 熒光素標記磷酸化蛋白激酶C β1/β2抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Horse IgG (親和純化) 馬IgGMulti-class antibodies規(guī)格： 10mg

庚型肝炎病毒抗體 Anti-HGV 0.2ml

Rabbit anti-mouse Kappa light chain 兔抗小鼠k鏈 1mg

FAM92A1 英文名稱： FAM92A1蛋白抗體 0.2ml

Rhesus antibody Rh phospho-ROCK2(Tyr256) 磷酸化Rho相關(guān)蛋白激酶2抗體 規(guī)格 0.1ml

Horse IgG (親和純化) 馬IgGMulti-class antibodies規(guī)格： 10mg

ANG 人緊張素Multi-class antibodies規(guī)格： 48T

Anti-CK16 細胞角蛋白16抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh NSDHL 類固醇脫氫酶樣蛋白NSDHL抗體 規(guī)格 0.2ml

PVDF(Polyvinylidene Fluoride Membrane) PVDF膜/二氟化樹脂膜(膜孔徑:0.45um) 15X20cm

TRIM41 英文名稱： 環(huán)指蛋白調(diào)節(jié)蛋白激酶C蛋白抗體 0.2ml

C9orf135 英文名稱： 9號染色體開放閱讀框135抗體 0.2ml

Anti-CK16 細胞角蛋白16抗體Multi-class antibodies規(guī)格： 0.1ml

MIF Protein Mouse 重組小鼠 MIF / Migration Inhibitory Factor 蛋白

MDA-MB-231 人癌細胞

IGSF11 Others Human 人 IGSF11 / BTIGSF 人細胞裂解液 (陽性對照)

SK-BR-3人腺癌細胞 SK-BR-3 human breast adenocarcinoma cells DMEM培養(yǎng)基+10%FBS

小鼠紅細胞;MEL

人胚胎氣管組織來源細胞;CCC-HBE-2 人肺泡上皮細胞完全培養(yǎng)基 100mL

CL-0288MA-891(小鼠癌高轉(zhuǎn)移細胞)5×106cells/瓶×2

CLEC4F Others Rat 大鼠 CLEC4F / CLECSF13 人細胞裂解液 (陽性對照)

人前脂肪細胞-內(nèi)臟cDNAHPA-v cDNA

BCaP-37細胞，人癌細胞 猴腎細胞系,MA-104細胞 腸內(nèi)皮細胞Many types of cells包裝：5 × 105次方(1ml)

TE-13(人細胞) 5×106cells/瓶×2

HBdMEC Pellet 人膀胱微內(nèi)皮細胞團塊 > 1 mio.cells 胰酶/EDTA消化液T/E

MED17抗體費用 MIF Protein Mouse 重組小鼠 MIF / Migration Inhibitory Factor 蛋白

MDA-MB-231 人癌細胞

IGSF11 Others Human 人 IGSF11 / BTIGSF 人細胞裂解液 (陽性對照)

SK-BR-3人腺癌細胞 SK-BR-3 human breast adenocarcinoma cells DMEM培養(yǎng)基+10%FBS

小鼠紅細胞;MEL

人胚胎氣管組織來源細胞;CCC-HBE-2 人肺泡上皮細胞完全培養(yǎng)基 100mL